| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2005 | WO2005013724A1 Aiding of cognitive function |
| 02/17/2005 | WO2005013691A1 Use of boranocarbonates for the therapeutic delivery of carbon monoxide |
| 02/17/2005 | WO2005002540A3 Dry powder pharmaceutical suspension compositions of cefuroxime axetil |
| 02/17/2005 | WO2004110993A3 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 02/17/2005 | WO2004110400A3 Implantable polymeric device for sustained release of nalmefene |
| 02/17/2005 | WO2004110399A3 Solvates of cefprozil |
| 02/17/2005 | WO2004110344A3 New azetidine compounds |
| 02/17/2005 | WO2004108892A3 1,1-DISUBSTITUTEDCYCLOALKYL-, GLYCINAMIDYL-, SULFONYL-AMIDINO-, AND TETRAHYDROPYRIMIDINYL-CONTAINING DIAMINOALKYL, β-AMINOACIDS, α-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS |
| 02/17/2005 | WO2004107958A3 Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
| 02/17/2005 | WO2004105837A3 Compounds and methods for improving platelet recovery and function |
| 02/17/2005 | WO2004103407A3 Composition comprising a pde4 inhibitor and a pde5 inhibitor |
| 02/17/2005 | WO2004103358A3 Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| 02/17/2005 | WO2004096982A3 Antibacterial agents |
| 02/17/2005 | WO2004093781A3 Podophyllotoxin derivatives as igf-1r inhibitors |
| 02/17/2005 | WO2004092329A3 Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines |
| 02/17/2005 | WO2004092115A3 Hydroxamates as therapeutic agents |
| 02/17/2005 | WO2004091592A3 Methods and compositions to treat myocardial conditions |
| 02/17/2005 | WO2004091483A3 Once daily formulations of tetracyclines |
| 02/17/2005 | WO2004091280A3 Pharmaceutical compositions |
| 02/17/2005 | WO2004089395A3 Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease |
| 02/17/2005 | WO2004089351A3 Treatment of progressive neurological disorders comprising a mao inhibitor (miclobemid) and an acetylcholinesterase inhibitor (tacrin) |
| 02/17/2005 | WO2004089306A3 Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| 02/17/2005 | WO2004087173B1 Formulations for mediating inflammation and for reducing blood cholesterol |
| 02/17/2005 | WO2004087132A3 Combination drug therapy for treating hypertension |
| 02/17/2005 | WO2004080391A3 Novel antibacterial agents |
| 02/17/2005 | WO2004078114A3 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists. |
| 02/17/2005 | WO2004073767A3 Regulation of blood pressure by coded nerve signals |
| 02/17/2005 | WO2004073645A3 Inhibition of olfatory neurosensory function of treat eating disorders and obesity |
| 02/17/2005 | WO2004071423A3 Methods of administering opioid antagonists and compositions thereof |
| 02/17/2005 | WO2004069991A3 Oligomeric compounds for the modulation of survivin expression |
| 02/17/2005 | WO2004063330A3 (2-carboxamido) (3-amino) thiophene compounds |
| 02/17/2005 | WO2004052401A3 Compositions and methods of delivery of pharmacological agents |
| 02/17/2005 | WO2004041181A3 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration |
| 02/17/2005 | WO2004037193A3 Chromones and chromone derivatives and uses thereof |
| 02/17/2005 | WO2004021967A3 Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
| 02/17/2005 | WO2004016805A3 Immunostimulatory nucleic acids |
| 02/17/2005 | WO2004016578A8 Arylethanolamine beta2-adrenoreceptor agonist compounds |
| 02/17/2005 | WO2004005457A3 Tfc/ beta-catenin regulated genes for treating cancer |
| 02/17/2005 | WO2004002999A8 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 02/17/2005 | WO2004002491A8 Morpholine and tetrahydropyran drivatives and their use as cathepsin inhibitors |
| 02/17/2005 | WO2003106449A8 Novel aryl-{4-halo-4-[heteroarylmethylamino)-methyl]-piperidin-1-yl}-methanone derivatives, methods for production and use thereof as medicaments |
| 02/17/2005 | WO2003099192A8 Bis-aromatic alkanols |
| 02/17/2005 | WO2003097059A8 Polymorphic forms of phenyl oxazolidinone derivatives |
| 02/17/2005 | WO2003080568A3 Probucol derivatives |
| 02/17/2005 | WO2003070910A3 INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/17/2005 | US20050038505 Drug-delivery endovascular stent and method of forming the same |
| 02/17/2005 | US20050038504 Dip coating stent and/or catheter having complex configuration utilizing aqueous latex polymeric emulsions; reducing material loss; customized variable dosing |
| 02/17/2005 | US20050038270 Methods for producing sterol ester-rich compositions |
| 02/17/2005 | US20050038259 Elastase release inhibitors; such as 19-(1H-tetrazol-5-yl)nonadec-6-en-5-ol |
| 02/17/2005 | US20050038256 Synthetic process for trans-aminocyclohexyl ether compounds |
| 02/17/2005 | US20050038249 metal complexes used as prodrugs that may be activated under hypoxic conditions by enzymes or by radiotherapy for treatment of cancer |
| 02/17/2005 | US20050038248 Chemotherapeutic agents |
| 02/17/2005 | US20050038247 topoisomerase inhibitors such as [5-(4-Cyclopropylcarbamoyl-imidazol-1-yl)-7-pyrimidin-2-yl-1H-benzoimidazol-2-yl]-carbamic acid ethyl ester, used for prophylaxis of bacterial infections in mammals |
| 02/17/2005 | US20050038243 2, 4-pyrimidinediamine compounds and their uses |
| 02/17/2005 | US20050038242 Pyrrolothiazine and pyrrolothiazephine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 02/17/2005 | US20050038126 Administering mammal a bicyclo [3.2.1]octan in a double ring system having kaurene structure such as steviol, isosteviol and stevioside; synergistic mixture with soy protein, and/or fiber and/or isoflavone |
| 02/17/2005 | US20050038125 Treating disorders with elevated prostaglandin E2 and leukotriene levels with pterostilbene derivative; antiinflammatory, antihistamine, and bronchodilator agents; osteoarthritis, fibromyalgia, rheumatic arthritis, psoriasis |
| 02/17/2005 | US20050038124 Highly pure modafinil |
| 02/17/2005 | US20050038122 Phenyl naphthol ligands for thyroid hormone receptor |
| 02/17/2005 | US20050038121 Abuse resistant lysine amphetamine compounds |
| 02/17/2005 | US20050038120 for inhibiting or modulating nitric oxide synthesis; nitric oxide synthase inhibitor; rheumatoid and osteoarthritis; inflammatory bowel disease; asthma |
| 02/17/2005 | US20050038119 for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion |
| 02/17/2005 | US20050038118 Treatment |
| 02/17/2005 | US20050038116 Novel class of compounds (Choline derivatives, esp. Stearyl Choline Cloride and other salts) for the treatment of Alzheimer's disease, Down syndrome and central (and/or peripheral) nervous system and memory related disorders or for enhancements |
| 02/17/2005 | US20050038115 Helianthrone derivatives as anti-cancer agents |
| 02/17/2005 | US20050038113 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease |
| 02/17/2005 | US20050038112 prevention, control and treatment of cancer; leukemia |
| 02/17/2005 | US20050038111 4'-cyano- alpha ', alpha ', alpha '-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide; anti-oestrogen (eg, tamoxifen citrate) and/or an aromatase inhibitor (eg, anastrozole); preventing side effect; bioavailability; storage stability; prostate cancer |
| 02/17/2005 | US20050038110 Selective androgen receptor modulators and methods of use thereof |
| 02/17/2005 | US20050038109 treatment of solid tumor cancers |
| 02/17/2005 | US20050038108 4S, 5R, 6R)-5-Acetylamino-4-azido-6-[(S)-4-nitrophenoxycarbonyloxy)-(2-oxo-[1,3]dioxolan-4R-yl)methyl]- 5,6-dihydro-4H-pyran2-carboxylic acid methylester; modified at the carboxyl or hydroxyl or amino functions; orthomyxovirus and paramyxovirus infections; a long lung residency time and high potency |
| 02/17/2005 | US20050038106 polyketides; for inhibiting proliferation of lung cancer or leukemia cells |
| 02/17/2005 | US20050038105 non-peptide molecules, comprising side chains of amino acids, capable of adopting a helicoidal structure independent of the primary structure of the molecules; mimics active natural helices |
| 02/17/2005 | US20050038104 Substitute benzothiophene compounds |
| 02/17/2005 | US20050038103 improve visual acuity and visual field ; corneal dystrophy; cataracts; retinitis pigmentosa |
| 02/17/2005 | US20050038102 cardiovascular disease or a cerebrovascular disease; pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome |
| 02/17/2005 | US20050038101 Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases |
| 02/17/2005 | US20050038098 Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
| 02/17/2005 | US20050038096 include a benzimidazole (mebendazole, fenbendazole, omeprazole), a polyol (polyethylene glycol), and a dipolar aprotic solvent (N,N-dimethylacetamide or dimethylsulfoxide); improved drug solubility, drug release from the formulation, and bioavailability |
| 02/17/2005 | US20050038095 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 02/17/2005 | US20050038093 Treating diabetic retinopathy with angiotensin II receptor blockers |
| 02/17/2005 | US20050038092 effective against aerobic and anerobic pathogens such as multi-resistant staphylococci, streptococci and enterococci, Bacteroides spp., Clostridia spp. species; side effect reductions |
| 02/17/2005 | US20050038087 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| 02/17/2005 | US20050038085 Substituted benzimidazole antiviral agents |
| 02/17/2005 | US20050038084 Phenylalanine enamide derivatives |
| 02/17/2005 | US20050038083 Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias |
| 02/17/2005 | US20050038080 Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| 02/17/2005 | US20050038079 Nicotine receptor agonists in stem cell and progenitor cell recruitment |
| 02/17/2005 | US20050038078 Antimetastasis agents e.g. 6-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-N-pyridin-2-ylmethyl-nicotinamide; protein kinase inhibitor |
| 02/17/2005 | US20050038077 use of pharmaceutically acceptable organic acids with a water solubility >1 g/250 mL at 20 degrees C., in solid oral formulations leads to a improved galenic form of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate |
| 02/17/2005 | US20050038071 Solenopsin a, b and analogs and as novel angiogenesis inhibitors |
| 02/17/2005 | US20050038070 Tetrahydroquinoline derivatives; modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer |
| 02/17/2005 | US20050038069 Tumor necrosis factor antagonist; antiinflammatory agents; such as 2-Cyclopropyl-4-(3,5-dimethyl-4-pyridylmethoxy)-7-methoxy-3H-benzimidazole |
| 02/17/2005 | US20050038068 Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
| 02/17/2005 | US20050038066 Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors |
| 02/17/2005 | US20050038063 Method of treating acute pain with unitary dosage form comprising ibuprofen and oxycodone |
| 02/17/2005 | US20050038062 Methods and materials for the treatment of pain comprising opioid antagonists |
| 02/17/2005 | US20050038061 6-Aminomorphinane derivatives, method for production and use thereof |
| 02/17/2005 | US20050038060 Spiropoperidine compounds as ligands for orl-1 receptor |
| 02/17/2005 | US20050038058 Novel compounds and methods for therapy |